VRTX Stock Price and Chart — CAPITALCOM:VRTX — TradingView

Overview

News Ideas Discussions Seasonals

VRTX chart

Key facts today

Vertex Pharmaceuticals halted clinical trials for its Type 1 diabetes treatment, VX-264, after failing to achieve its main efficacy goal, with no notable rise in C-peptide levels.

Vertex Pharmaceuticals Inc. disclosed in an SEC filing that it anticipates a $400 million impairment charge associated with its VX-264 program.

Analyze the impact Analyze the impact

Ideas

See all ideas

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

Curated watchlists where VRTX is featured.

Biotech stocks: A shot in the arm

Female-led stocks: Who rules the world?

34 No. of Symbols

See all sparks